Allergan's bitter pill for Morgan Stanley

Allergan, which is fending off a $53 billion takeover bid by Valeant, released emails sent by senior Morgan Stanley bankers appearing to denigrate Valeant and its business strategy

Tuesday 17 June 2014 at 15:23

The mudslinging between Allergan and Valeant got more intense on Monday. But it was Morgan Stanley bankers who found themselves caught in the crossfire.

Allergan, which is fending off a $53 billion takeover bid by Valeant, released emails sent by senior Morgan Stanley bankers appearing to denigrate Valeant and its business strategy.